CD8A and neoplasm: In the analysis of antitumor immunity using the tumor tissues of both sides harvested 14 days after the first OBP-702 injection, the combination therapy of butyrate and OBP-702 tended to increase CD8 + T cells, CD8 + IFN-γ + T cells, and Granzyme B expression in the tumor tissues on both sides.